Literature DB >> 1268851

The effect of adriamycin on the cell cycle traverse of a human lymphoid cell line.

B Barlogie, B Drewinko, D A Johnston, E J Freireich.   

Abstract

The kinetic response of a human lymphoma cell line to adriamycin was analyzed by means of pulse cytophotometry. Depending on concentration and exposure time, cell cycle progression was delayed in G1, S, and G2 phases. There was a differential sensitivity for the interaction of adriamycin with the transit through these phases. G2 arrest could be induced by low concentrations of adriamycin, whereas the block in G1 was exerted only after long-term treatment with high concentrations and was completely reversible after drug removal. Delay in S-phase transit was transient in spite of continuous exposure to high concentrations of adriamycin. Thus, concentration and duration of treatment determined the magnitude of G2 arrest as well as onset and rate of G2 accumulation due to progression delay in G1 and S phases. Cell age had only little influence on the degree of subsequent G2 arrest. Irreversibility of the G2 block strongly suggests eventual cell death in G2 phase, which may be utilized as a predictive test for response to adriamycin in vivo.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1268851

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Influence of the G2 cell cycle block abrogator pentoxifylline on the expression and subcellular location of cyclin B1 and p34cdc2 in HeLa cervical carcinoma cells.

Authors:  T Theron; L Böhm
Journal:  Cell Prolif       Date:  2000-02       Impact factor: 6.831

2.  Topoisomerase-specific drug sensitivity in relation to cell cycle progression.

Authors:  K C Chow; W E Ross
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

3.  Comparison of autoradiography and DNA histograms in assessing S-phase cells from patients with myeloid leukemias.

Authors:  A Raza; A S Raza; K Kuliczkowski; S C Zhao; H D Preisler
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

Review 4.  The molecular basis of drug-induced G2 arrest in mammalian cells.

Authors:  P N Rao
Journal:  Mol Cell Biochem       Date:  1980-01-16       Impact factor: 3.396

5.  A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.

Authors:  Adam C Palmer; Christopher Chidley; Peter K Sorger
Journal:  Elife       Date:  2019-11-19       Impact factor: 8.140

6.  Potent antiviral activity of topoisomerase I and II inhibitors against Kaposi's sarcoma-associated herpesvirus.

Authors:  Lorenzo González-Molleda; Yan Wang; Yan Yuan
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

Review 7.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

8.  The cytokinetic and cytotoxic effects of ICRF-159 and ICRF-187 in vitro and ICRF-187 in human bone marrow in vivo.

Authors:  R H Wheeler; D J Clauw; R B Natale; R W Ruddon
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

9.  The effect of NC-190, a novel antitumor compound, on the cell-cycle progression of HeLa S3 cells.

Authors:  T Yamagishi; S Nakaike; K Nanaumi; S Otomo; S Tsukagoshi
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Initial and early effects of adriamycin in murine sarcoma 180 cannot be restored in a resistant subline by increasing the uptake and external concentration of the drug.

Authors:  J Sonka; U Schossig; M Vogt-Schaden; M Volm
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.